deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT04527549

Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

The BAMM2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib With or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma With Elevated LDH

Sponsor: ECOG-ACRIN Cancer Research Group

Conditions Clinical Stage IV Cutaneous Melanoma AJCC v8 Locally Advanced Melanoma Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 Pathologic Stage IV Cutaneous Melanoma AJCC v8 Unresectable Melanoma
Interventions Dabrafenib mesylate Hydroxychloroquine Placebo Administration Trametinib dimethyl sulfoxide
Updated 13 times since 2020 Last updated: Feb 27, 2026 Started: Jun 1, 2021 Primary completion: Jan 8, 2024 Completion: Jan 8, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow accrual

Other terminated trials from ECOG-ACRIN Cancer Research Group

More terminations from ECOG-ACRIN Cancer Research Group

Other Clinical Stage IV Cutaneous Melanoma AJCC v8 trials with similar outcome

Browse all Clinical Stage IV Cutaneous Melanoma AJCC v8 trials

This PHASE2 trial investigates Clinical Stage IV Cutaneous Melanoma AJCC v8 and Locally Advanced Melanoma and is currently terminated or withdrawn. ECOG-ACRIN Cancer Research Group leads this study, which shows 13 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2022 · 13 months · monthly snapshot~Feb 2022 – ~Nov 2022 · 9 months · monthly snapshot~Nov 2022 – ~Jul 2023 · 8 months · monthly snapshot~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – ~Feb 2026 · 2 months · monthly snapshot~Feb 2026 – ~Mar 2026 · 28 days · monthly snapshot~Mar 2026 – present · 4 months · monthly snapshot

Change History

13 versions recorded

  1. Mar 2026 — Present [monthly]

    Terminated PHASE2

  2. Feb 2026 — Mar 2026 [monthly]

    Terminated PHASE2

  3. Dec 2025 — Feb 2026 [monthly]

    Terminated PHASE2

  4. Sep 2025 — Dec 2025 [monthly]

    Terminated PHASE2

  5. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

▶ Show 8 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Jul 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Nov 2022 — Jul 2023 [monthly]

    Active Not Recruiting PHASE2

  4. Feb 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE2

  5. Jan 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  7. Oct 2020 — Nov 2020 [monthly]

    Not Yet Recruiting PHASE2

  8. Sep 2020 — Oct 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ECOG-ACRIN Cancer Research Group
  • National Cancer Institute (NCI)
Data source: Eastern Cooperative Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United States , Alton, United States , Ames, United States , Anchorage, United States , Arroyo Grande, United States , Aurora, United States , Aventura, United States , Ballwin, United States , Baltimore, United States , Bardstown, United States and 130 more locations